Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03802851 · ClinicalTrials.gov registry record · NA

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

A NA study of Prostate Cancer and Lower Urinary Tract Symptoms, sponsored by University of Kansas Medical Center.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03802851 is a NA study of Prostate Cancer and Lower Urinary Tract Symptoms that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03802851, a NA study of Prostate Cancer and Lower Urinary Tract Symptoms, is actively recruiting participants, sponsored by University of Kansas Medical Center.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.

Interventions

  • PROCEDURE Holmium Laser Enucleation of Prostate (HoLEP)

Study Locations (1)

Kansas

  • University of Kansas Health System - Kansas City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-09-19
Est. Completion 2035-01
Phase NA

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT03802851

The ClinicalTrials.gov registry entry for NCT03802851 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Holmium Laser Enucleation of Prostate (HoLEP) is the first listed.

NCT03802851 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT03802851 about?

NCT03802851 is a clinical study titled "HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer". To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.

What is the current status of trial NCT03802851?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-09-19. Estimated completion is 2035-01.

What conditions does trial NCT03802851 study?

This clinical trial studies the following conditions: Prostate Cancer, Lower Urinary Tract Symptoms.

What interventions are being tested in trial NCT03802851?

The interventions under investigation include: Holmium Laser Enucleation of Prostate (HoLEP) (PROCEDURE).

Who is sponsoring clinical trial NCT03802851?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03802851 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.